FRONTIERS IN CNS THERAPEUTIC DEVELOPMENT

Disorders of the central nervous system (CNS) have steadily increased over the past 30 years, with neurological disease now constituting the world’s leading cause of disability and health burden.

Despite the number of organizations developing potentially transformative therapies to address these diseases, most drugs designed to treat neurological illness struggle to cross the brain’s protective barrier – known as the blood-brain barrier (BBB).  

Various approaches are being explored to overcome this pharmacological challenge. The DNB//Back Bay Partnership analyzed the clinical development landscape, recent transactions, and financing activity to better understand which technologies are advancing to the clinic and gaining traction. 

Read More